Trial reportThe Indian journal of tuberculosis2026
Patient experiences and motivations in tuberculosis treatment: Insights from a digital adherence technology trial.
Trial report in The Indian journal of tuberculosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Non-adherence to Tuberculosis (TB) treatment remains a global health challenge, particularly in low- and middle-income countries. Digital Adherence Technologies (DATs) have shown promise in improving treatment outcomes, yet little is known about user perceptions. Through an exit survey, this study evaluated the acceptability to participants of the Tuberculosis Treatment Support Tools intervention, which combines a mobile app for reporting of medication, direct contact with healthcare team, and a metabolite test to support self-administered TB treatment in Argentina. A pragmatic clinical trial was conducted at four public hospitals in Buenos Aires, in which 80 participants completed exit surveys. The app was rated highly for ease of use (4.3/5) and was strongly recommended to others (4.7/5). Features like medication reminders, direct messaging with treatment supporters, and an anonymous patient forum were praised for enhancing adherence and reducing isolation. The metabolite test, generally well-received, faced minor usability challenges. Participants highlighted need for simplified reporting and improved reminders. Motivation for adherence stemmed from health improvement goals, family support, and professional guidance. Recommendations for improvement included personalized features and addressing technical barriers. The intervention demonstrates potential for enhancing adherence by meeting practical and emotional needs, offering insights for the refinement of digital tools in TB treatment care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.